-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MPC-75IA in Pain
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.MPC-75IA in PainDrug Details:MPC-75-IA (MSB-CAR001) is under development for the treatment of knee osteoarthritis, pain and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MPC-300IV in Rheumatoid Arthritis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.MPC-300IV in Rheumatoid ArthritisDrug Details:MPC-300-IV (rexlemestrocel-L) is under development for the treatment of type 2 diabetes,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MPC-300IV in Type 2 Diabetes
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.MPC-300IV in Type 2 DiabetesDrug Details:MPC-300-IV (rexlemestrocel-L) is under development for the treatment of type 2...
-
Product Insights
MPC Ppty – Navigator Business Center Phase II – Central Serbia
Equip yourself with the essential tools needed to make informed and profitable decisions with our MPC Ppty - Navigator Business Center Phase II - Central Serbia report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
Renewable ES Canada – Enterprise MPC Solar 100 MW – Alberta
Equip yourself with the essential tools needed to make informed and profitable decisions with our Renewable ES Canada - Enterprise MPC Solar 100 MW - Alberta report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
MPC Eng – Santo Domingo Solar Power Plant 100 MW – Santo Domingo
Equip yourself with the essential tools needed to make informed and profitable decisions with our MPC Eng - Santo Domingo Solar Power Plant 100 MW - Santo Domingo report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rexlemestrocel-L in Chronic Heart Failure
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rexlemestrocel-L in Chronic Heart Failure Drug Details: Rexlemestrocel-L is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cell Therapy For Urinary Stress Incontinence in Stress Urinary Incontinence
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cell Therapy for Urinary Stress Incontinence in Stress Urinary Incontinence Drug Details: Cell therapy...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rexlemestrocel-L in Left Ventricular Dysfunction
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rexlemestrocel-L in Left Ventricular Dysfunction Drug Details: Rexlemestrocel-L is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PXL-065 in Non-Alcoholic Steatohepatitis (NASH)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PXL-065 in Non-Alcoholic Steatohepatitis (NASH)Drug Details:PXL-065 is under development for the treatment of non-alcoholic steatohepatitis (NASH),...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Remestemcel-L in Ulcerative Colitis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Remestemcel-L in Ulcerative Colitis Drug Details: Remestemcel-L (Prochymal, Temcell) is a stem cell drug therapy....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bittera in Obesity
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bittera in Obesity Drug Details: Bittera is under development for the treatment of metabolic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – A-3907 in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. A-3907 in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drug Details: A-3907 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – COT-143 in Resistant Pseudomonas aeruginosa Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.COT-143 in Resistant Pseudomonas aeruginosa InfectionsDrug Details:COT-143 is under development for the treatment of resistant pseudomonas...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – REACT in Type 1 Diabetes (Juvenile Diabetes)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.REACT in Type 1 Diabetes (Juvenile Diabetes)Drug Details:REACT is under development for the treatment of chronic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGB-10188 in Marginal Zone B-cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGB-10188 in Marginal Zone B-cell Lymphoma Drug Details: BGB-10188 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – STP-707 in Colon Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. STP-707 in Colon Cancer Drug Details: STP-707 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Surufatinib in Neuroendocrine Tumors
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Surufatinib in Neuroendocrine Tumors Drug Details: Surufatinib (Sulanda) is a potential antineoplastic and anti-angiogenic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ecubectedin in Soft Tissue Sarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Ecubectedin in Soft Tissue Sarcoma Drug Details:Ecubectedin (PM-14) is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Itacitinib Adipate in Myeloproliferative Disorders
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Itacitinib Adipate in Myeloproliferative Disorders Drug Details: Itacitinib adipate (INCB-39110) is under development for the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.